

Thyroid cancer Committee meeting 10

Date: 22/09/21 10:00-16:00

Location: Virtual meeting

Minutes: Confirmed

Committee members present:				
Richard Grünewald [RG] – Chair	(Present for notes 1 – 5)			
Jeremy Davis [JD] – Topic advisor	(Present for notes 1 – 5)			
John Buscombe [JB]	(Present for notes 1 – 5)			
Preetha Chengot [PC]	(Present for notes 1 – 5)			
Neil Cozens [NC]	(Present for notes 1 – 5)			
Fiona Eatock [FE]	(Present for notes 1 – 5)			
Kate Farnell [KF]	(Present for notes 1 – 3)			
Steve Hyer [SHY]	(Present for notes 1 – 5)			
Kate Newbold [KN]	(Present for notes 1 – 5)			
Sonja Hoy [SH]	(Present for notes 1 – 5)			
Iain Nixon [IN]	(Present for notes 1 – 5)			
Anh Tran [AT]	(Present for notes 1 – 4)			

In attendance:			
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 5)	
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 5)	
Caroline Charlton [CC]	NICE Guideline Commissioning Manager	(Present for notes 4 – 5)	
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 5)	
Sophie Carlisle [SC]	Research Fellow	(Present for note 4)	
Yasmina Hedhli [YH]	Project Manager	(Present for notes 1 – 5)	

Apologies:		
Jessica Lishak (JL)	Lay Member	
Lina Gulhane [LG]	Head of Information Specialists	

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the tenth meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included:

- FNAC with or without rapid on-site assessment or core following ultrasound
- Repeat FNAC, diagnostic hemithyroidectomy, active surveillance or discharge

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were FNAC with or without rapid on-site assessment or core following ultrasound and repeat FNAC, diagnostic hemithyroidectomy, active surveillance or discharge.

New declarations were received from JD, SH and KN.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Jeremy Davis	Consultant in Otolaryngology, Head and Neck Surgery, Medway NHS Foundation Trust	Co-author of the following paper, which has been accepted for publication. Relates to thyroid, but not to the work of the guideline committee.	Direct, non- financial, professional and personal.	Non- specific. Declare and participate.
		Management of haematoma after thyroid surgery: systematic review and multidisciplinary consensus guidelines from the Difficult Airway Society, the British Association of Endocrine and Thyroid Surgeons and the British Association of Otorhinolaryngology, Head and Neck Surgery 22 September 2021		
Jeremy Davis	Consultant in Otolaryngology, Head and Neck	Co-author of the following paper, which has been accepted for publication. Relates to thyroid, but not to	Direct, non- financial, professional	Non- specific. Declare

	Surgery, Medway NHS Foundation Trust	the work of the guideline committee. The United Kingdom thyroid multi-disciplinary team: A national survey of services and comparison to guidelines 22 September 2021	and personal.	and participate.
Sonja Hoy	Lead Nurse for Head Neck and Thyroid Oncology and Radiation Protection, The Royal Marsden NHS Foundation Trust	Steering committee member for Eisai's European prehabilitation programme for people who need to start TKI treatment for any thyroid cancer. The programme aims to support the understanding, delivery and utilisation of prehabilitation ahead of systemic therapy initiation in thyroid cancer patients across Europe. (Following committee meeting the member withdrew from this project). 22 September 2021	Direct, financial.	Non- specific. Declare and participate.
Kate Newbold	Consultant Clinical Oncologist Head & Neck and Thyroid, The Royal Marsden NHS Foundation Trust, London and Sutton, and Senior Lecturer Institute of Cancer Research, London	Asked to chair an advisory board for Ipsen looking at iodine refractory thyroid cancer and second line drugs. KN is not taking an honorarium for this. 22 September 2021	Direct, non- financial, professional and personal.	Non- specific. Declare and participate.

The Chair and a senior member of the Developer's team noted that none of these interests represented a conflict and therefore did not prevent full participation in the meeting.

The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.

3. Evidence review: FNAC with or without rapid on-site assessment or core

following ultrasound

MP presented the evidence for diagnostic accuracy of ultrasound. AM presented the economic evidence. The GC drafted recommendations.

4. Evidence review: Repeat FNAC, diagnostic hemithyroidectomy, active surveillance or discharge

SC presented the evidence for diagnostic accuracy of ultrasound. AM presented the economic evidence. The GC drafted recommendations.

5. Any other business

CS mentioned that definitions would need to be created for the guideline.

CS asked for volunteers to write chapter introductions.

Date of next meeting:

23 September 2021

Location of next meeting: Virtual meeting